/

ANRO

Alto Neuroscience, Inc.Closed

22.09−2.06 −8.53%USD

NYSE · as of Oct 13, 16:00 ET · 20m delayAfter hours 22.30 +0.95%

Open

24.04

Prev close

24.15

Day range

22.0724.20

52-week range

5.5637.48

Volume

663.30K1.29×

Mkt cap

866.86M

P/E ttm

—

Fwd P/E

-6.72

EPS ttm

-2.31

Div yield

0.00%

Earnings

—

From 52w high

−41.06%

Price Chart

Yahoo Finance · delayed

ANROOct 13, 2026O 24.04H 24.20L 22.07C 22.09−2.06 (−8.53%)Vol 661.80K

SMA 5030.38
SMA 20023.88

1Y change +291.67% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ANRO Alto Neuroscience, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.75%
1 month: −30.97%
3 months: −20.54%
6 months: −14.45%
Year to date: +24.10%
1 year: +275.68%

Valuation & ownership

Market cap: 866.86M
Enterprise value: 646.42M
P/E (ttm): —
Forward P/E: -6.72
PEG ratio: —
Price / book: 3.54
Price / sales (ttm): —
EV / EBITDA: -7.38
EPS (ttm): -2.31
EPS (forward): -3.29
Beta (5y monthly): 1.34
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 39.24M
Float: 29.59M
Short % of float: 13.91%
Short ratio (days): 7.73
Held by insiders: 4.21%
Held by institutions: 87.11%
Avg volume (3m): 512.40K
50-day average: 30.48
200-day average: 23.86
52-week change: +275.68%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 22.5
vs 50-day SMA: −27.29%
vs 200-day SMA: −7.48%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.81%
Realised vol (20d, ann.): 54.6%
From 52-week high: −41.06%
From 52-week low: +322.78%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.18 on a 1 (strong buy) – 5 (sell) scale

Mean target

38.38

+73.75% implied

Low 26.00Median 37.00High 55.00

Recommendation trend

Now10 / 1 / 0
1m ago10 / 1 / 0

DES

About Alto Neuroscience, Inc.

Yahoo Finance profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 68
Headquarters: Mountain View, CA, United States
Website: altoneuroscience.com
Officers: Dr. Amit Etkin M.D., Ph.D. Founder, CEO & Chairman of the Board
Mr. Nicholas C. Smith

SEAS

Seasonality · ANRO

2024–2026 · monthly returns

Strongest month Oct +93.49%Weakest month Feb −34.73%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-13.0	27.2	14.2	14.1	-21.8	31.5	2.6	30.7	-27.8	-13.5			+24.1%
2025	1.4	-34.7	-22.9	15.3	3.6	-14.7	39.5	19.9	9.2	253.0	-2.4	28.5	+320.8%
2024			-0.3	1.0	-22.9	-10.6	0.8	18.8	-10.7	-66.0	13.4	-4.1	−72.5%

INSD

Insider Activity · ANRO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 1, 2026	Smith Nicholas ConradPresident	Conversion of Exercise of derivative security at price 2.32 per share.	55K	$127.60K
May 13, 2026	Etkin AmitChief Executive Officer	Stock Gift at price 0.00 per share.	400K	—

13F

Investors Holding ANRO

latest 13F filings of 29 followed managers

Investors holding ANRO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.9M	0.00%	71.40K	−31%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ANRO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ANRO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alto Neuroscience, Inc.

Seasonality · ANRO

Insider Activity · ANRO

Congress Trades · ANRO

Investors Holding ANRO

Investors Holding ANRO

Congress Trades · ANRO

Insider Activity · ANRO

Seasonality · ANRO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alto Neuroscience, Inc.

Financial Snapshot

Earnings & Dividends

News